Boryung’s hypertension drug is in full swing in Latin America

Boryung’s hypertension drug is in full swing in Latin America. September. 27, 2016 07:37. by 김성모 기자.

“We have actively strived to make inroads into the Central and South American markets and achieved some results. We have done this as we saw the future there in every respect, including economic and cultural development.”

Boryung Pharmaceutical Company Chairman Kim Seung-ho (84) told reporters Monday at the press conference on exports of its hypertension drug held in COEX in southern Seoul. In the conference, Boyung signed a contract with Mexico's Stendhal to supply mixture of hypertension drugs named “Dukarb” and “Tubero,” of which account for 27.23 million U.S. dollars. Along with the chairman, President Choi Tae-hong and Stendhal CEO Carlos Arenas Wiedfeldt attended the event.

The 26th Scientific Meeting of the International Society of Hypertension, which is dubbed "the Olympics of hypertension," is held in COEX. Boryung is the main sponsor of the event. “When the 2010 meeting was held in Vancouver, Canada, I firmly believed that 'Kanarb' would be the main player for the treatment of high blood pressure," Boryung's chairman said. "I’m very excited as the company supports such a big event and signed the contract.”

Anti-hypertension mixture “Ducarb” and “Tubero,” treatment drug for high blood pressure and hyperlipidemia, are follow-up drugs of Boryung’s homegrown hypertension drug “Kanarb,” which was approved in South Korea in 2010.

With this signing on the contract, Boryung's drugs will be sold in 25 markets of the Central and South America, including Chile and Uruguay. Currently, the Korean pharmaceutical company is selling “Kanarb” and diuretic mixture “Kanarb Plus” in 12 Latin American countries including Mexico. The high blood pressure treatment drugs have achieved a record of 375.3 million dollars in export.

Boryung has revealed its plan to knock on doors to European and Southeast Asian markets. The company will seek an approval to sale its drugs to Russia in the second half of this year, while it is looking for local partners to advance into the Philippines and other Southeast Asian markets in the first half of next year.